Definium Therapeutics Inc (DFTX) Says Cash Enough to Fund Operations into 2028

Group 1 - Definium Therapeutics Inc (NASDAQ:DFTX) is recognized as a promising psychedelic stock for investment in 2026, with its lead drug candidate DT120 in Phase 3 trials targeting major depressive disorder (MDD) and generalized anxiety disorder (GAD) [1][5] - The company plans to host an Investor and Analyst Day on April 22 to discuss updates on the DT120 program and explore commercial opportunities [2] - In 2025, the company reported R&D expenditures of $117.7 million and general administrative costs of $48.6 million, ending the year with $411.6 million in cash and equivalents, sufficient to fund operations until 2028 [3][8] Group 2 - Enrollment for the Emerge Phase 3 MDD trial for DT120 has been completed, with topline data expected in late Q2 2026; enrollments for two Phase 3 GAD trials are also progressing well [4] - The Phase 2a trial for DT402, which targets autism spectrum disorder, began in Q4 2025, with initial data anticipated in 2026 [4]